title: Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity.
abstract: OBJECTIVE
  To report the 1-year results of intravitreal ranibizumab (IVR) injections for neovascular age-related macular degeneration (nAMD) in patients with good baseline visual acuity (VA).
  
  
  METHODS
  Thirty-six eyes of 36 patients with nAMD with best-corrected VAs (BCVAs) >0.6 (equal to 0.22 in the logarithm of the minimum angle of resolution unit) were enrolled. IVR was the primary treatment; additional treatment was administered as needed. BCVAs and central retinal thickness (CRT) were measured periodically.
  
  
  RESULTS
  The mean number of injections at month 12 was 3.3. The mean BCVAs were 0.11 ± 0.02 at baseline and 0.12 ± 0.03 at month 12, which did not significantly differ. The mean CRT significantly improved from 320 ± 15 to 254 ± 12 μm at month 12 (p < 0.01). Photodynamic therapy was applied in 2 cases because of frequent recurrences.
  
  
  CONCLUSIONS
  IVR maintained VA and improved morphological changes in wet AMD with good baseline VA.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
authors.forename: Aki
authors.initials: A
authors.lastname: Kato
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Yasukawa
authors.forename: Keiji
authors.initials: K
authors.lastname: Suga
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Hirano
authors.forename: Miho
authors.initials: M
authors.lastname: Nozaki
authors.forename: Munenori
authors.initials: M
authors.lastname: Yoshida
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ogura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D012160:Retina / Q000473:pathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology*; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab